Pharma CRM Goes on the iPad and iPhone

Media-SoftMedia-Soft, CRM solutions provider for pharmaceutical companies, announced the launch of the native and offline iPhone adn iPad Pharma CRM application with advanced and unique features that increase the Sales Force effectiveness in pharma organizations.

"Fast, simple, functional and revolutionary are the main goals of our Sales Force Effectiveness solutions for the iPhone, iPad and iPod Touch platforms. Now every sales rep can handle customers offline on the iPad, iPhone or iPod Touch via Sales Vision iTouch application, it's so simple," commented Mr. Damir Safaric, Media-Soft CEO. "It is called Sales Vision iTouch, the best way for Pharma CRM that can revolutionize the pharma processes and increase the sales rep efficiency."

The Pharma CRM application has a simple and comfortable natural user interface that has retained all the functionality of the original Sales Vision® and in special the access to the database online and offline, all actions can be moved to the PC version through the user friendly and intuitive touch screen navigation. Also Sales Vision iTouch enables a parallel use of platforms, so a sales rep can use the iPhone or iPad on the sales field and when he arrives home he can add new information's via his PC version, Sales Vision 9 WIN.

"There are many reasons why Sales Vision CRM goes to the iPhone. Sales Vision® and iPhone are similar because they both have remained true to its roots. Both operate in niches and seek to satisfy their customers. Sales Vision® looks better than ever on iPhone. Also if you look ten years ago, the main add value and motivation factor for a sales rep was to gain a laptop. Times have changed and today the add value is to have the best Smartphone," concluded Mr. Safaric.

For further information, please visit:
http://www.media-soft.info

About Media-Soft
The story of Media Soft begins in 1996 when a visionary man started up a company that must be the best in the pharmaceutical field. Today that mission is done, Media-Soft operates in more then 30 countries worldwide, on 3 continents and has over 6.000 licensed users of its software Sales Vision®. Media Soft is established on many locations. The HQ is in Cakovec and London. We also have partners and support teams worldwide in following countries: Mexico City, Bratislava, Warszawa and Moscow. Some of the customer are Pfizer, Krka, Sandoz, Solvay, Abbott, Alkaloid, GSK, Nycomed, Roche, Bayer Schering Pharma and many others.

Most Popular Now

AstraZeneca takes next steps towards broad and equ…

AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements ...

Johnson & Johnson announces acceleration of it…

Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Calquence showed promising clinical improvement in…

Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved cl...

Super-potent human antibodies protect against COVI…

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus ...

New consortium EUbOPEN will provide tools to unloc…

Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to bet...

AstraZeneca to supply Europe with up to 400 millio…

AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 milli...

Up to 45 percent of SARS-CoV-2 infections may be a…

An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a ...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...

Gilead announces results from Phase 3 Trial of rem…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label st...

Mayo finds convalescent plasma safe for diverse pa…

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findi...